SCHEMBL6077438

SCHEMBL6077438

CNC(Cc1ccc(Cl)cc1)Cc1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.54
SLC6A3 Q01959 2/20 0.54
SLC6A4 P31645 3/20 0.52
TAAR1 Q96RJ0 3/20 0.48
OPRD1 P41143 1/20 0.43
OPRK1 P41145 1/20 0.43
IDO1 P14902 1/20 0.41
MME P08473 2/20 0.41
ACACB O00763 1/20 0.40
SLC18A2 Q05940 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
HTR2A P28223 1/20 0.39
HRH1 P35367 1/20 0.39
HTR2B P41595 1/20 0.39
CHRNA4 P43681 1/20 0.39
ACE P12821 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13323451 0.90 SLC6A4 (0.62) SLC6A2SLC6A3SLC6A4TAAR1
SCHEMBL13649762 0.88 SLC6A2 (0.47) SLC6A2SLC6A3SLC6A4TAAR1OPRD1
SCHEMBL26697417 0.88 SLC6A2 (0.47) SLC6A2SLC6A3SLC6A4TAAR1OPRD1
SCHEMBL26219875 0.88 SLC6A2 (0.47) SLC6A2SLC6A3SLC6A4TAAR1OPRD1
SCHEMBL21994674 0.82 MME (0.59) MMEACE
SCHEMBL21994675 0.82 MME (0.59) MMEACE
SCHEMBL21286088 0.80 TAAR1 (0.63) SLC6A2SLC6A3SLC6A4TAAR1ACACB
SCHEMBL7316113 0.80 TAAR1 (0.63) SLC6A2SLC6A3SLC6A4TAAR1ACACB
SCHEMBL178533 0.80 TAAR1 (0.63) SLC6A2SLC6A3SLC6A4TAAR1ACACB
Hydrochloric Acid SCHEMBL23524375 0.78 TAAR1 (0.61) SLC6A2SLC6A3SLC6A4TAAR1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890942-B2 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-10 US claimed
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY 2005-01-06 US claimed
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-6890942-B2 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-10 US disclosed
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY 2005-01-06 US disclosed
WO-2004103278-A2 ACYL SULFONAMIDES AS INHIBITORS OF HIV INTEGRASE BRISTOL-MYERS SQUIBB COMPANY (US) 2004-12-02 WO disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase ACSS2, ARSA, ASS1 SLC6A2 3628/4885SLC6A3 3002/4885SLC6A4 3732/4885
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF SLC6A2 3531/4885SLC6A3 3643/4885SLC6A4 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.